CLAIMS

1. A composition that comprises a compound against EGF receptor and a compound against the NeuGcGM3 ganglioside for use in the treatment of cancer.
2. The composition of claim 1 wherein the compound against the EGF receptor is a monoclonal antibody that recognizes the EGFR.
3. The composition of claim 2 wherein the compound against the EGFR is a monoclonal antibody that recognizes the EGFR.
4. The composition of claim 1 wherein the compound against the EGFR is an anti-EGFR vaccine.
5. The composition of claim 1 wherein the compound against NeuGcGM3 ganglioside is a vaccine.
6. The composition of claim 5 wherein the vaccine has NeuGcGM3/VSSP as active principle.
7. The composition of claim 5 wherein the vaccine is Racotumumab anti-idiotypic vaccine adjuvated with alumina.
8. The composition of claim 1 that comprises an EGFR vaccine and a vaccine against NeuGcGM3 ganglioside.
9. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.
10. The composition of claim 1 wherein the tumor is a cancer selected from the group comprising lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
11. Use of a compound against NeuGcGM3 ganglioside, and a compound against the EGFR, for the preparation of a medicament for retarding tumor growth in a patient, wherein said patient suffers from lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
12. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy.

13. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional chemotherapy.
14. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy and chemotherapy.
15. A kit of reagents for tumor therapy in which EGFR and NeuGcGM3 ganglioside targets are co-expressed, wherein said reagent kit comprises simultaneous, staggered or alternate administration of:

    (a): Compound against EGFR

    (b): Compound against NeuGcGM3 ganglioside

CLAIMS

1. A composition that comprises a compound against epidermal growth factor receptor (EGFR) and a vaccine against a N-glycolyl GM3 ganglioside (NeuGcGM3) ganglioside for use in the treatment of cancer.

2. The composition of claim 1 wherein the compound against the EGF receptor is a monoclonal antibody that recognizes the EGFR.

3. The composition of claim 2 wherein the monoclonal antibody that recognizes the EGFR is nimotuzumab.

4. The composition of claim 1 wherein the compound against the EGFR is an anti-EGFR vaccine.

5. The composition of claim 1 wherein the vaccine has NeuGcGM3/very small size particle as active principle.

6. The composition of claim 1 wherein the vaccine is racotumumab anti-idiotypic vaccine adjuvated with alumina.

7. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.

8. The composition of claim 7 wherein the tumor is a cancer selected from the group comprising lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.